A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful Neuropathy
Launched by JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, L.L.C. · Oct 8, 2009
Trial Information
Current as of June 09, 2025
Terminated
Keywords
ClinConnect Summary
This is a multicenter (study conducted at multiple sites), randomized (the study medication is assigned by chance), double-blind (neither investigator nor the patient knows the treatment that the patient receives), placebo-controlled (an inactive substance that is compared with the study medication to test whether the study medication has a real effect in clinical study), dose-ranging study (study carried out at different doses) to evaluate the analgesic efficacy, safety, and tolerability of multiple doses of JNJ-42160443 in patients with neuropathic pain, followed by a double-blind safety ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Chronic neuropathic pain (pain persistent for greater than 6 months) that is moderate to severe in the opinion of the investigator
- • Currently taking neuropathic pain medication limited to maximal allowed doses according to guidelines provided, but are not adequately controlled by standard of care
- • Currently not taking neuropathic pain medications because they are intolerable to, or not willing to use, standard of care
- • Mean average pain intensity score of at least 5, but less than 10, over 7 consecutive days on an 11-point numerical rating scale
- • Pain due to bilateral peripheral neuropathy caused by type 1 or type 2 diabetes mellitus
- • Required to have stable glycemic control
- Exclusion Criteria:
- • Patients with severe diabetic neuropathy defined by severe autonomic dysfunction or blood pressure instability Separate pain condition (e.g., joint osteoarthritis) that is more severe than their pain due to their diagnosis of Diabetic Peripheral Neuropathy
- • Patients with evidence of another neuropathic pain not under the study, such as pain resulting from post-traumatic neuralgia, post-surgical neuropathy, complex regional pain, sensory neuropathies or pain caused by radiation, chemotherapy, alcohol, Human Immunodeficiency Virus (HIV) infection
- • Major surgeries, trauma, and non-healing wounds/ulcers within 3 months prior to study medication
- • History of severe traumatic brain injury within the past 15 years
- • Other peripheral neuropathy, parasthesia or dyesthesia or previously diagnosed neurological condition causing these symptoms not related with diabetic painful neuropathy under study
About Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. is a leading global biopharmaceutical company dedicated to advancing medical innovation and improving patient outcomes. As a subsidiary of Johnson & Johnson, the organization focuses on the research, development, and commercialization of novel therapeutics across various therapeutic areas, including immunology, oncology, neuroscience, and infectious diseases. With a commitment to scientific excellence and collaboration, the company leverages cutting-edge technologies and a robust pipeline to address unmet medical needs and deliver transformative solutions that enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Antonio, Texas, United States
Winston Salem, North Carolina, United States
Philadelphia, Pennsylvania, United States
Houston, Texas, United States
Baltimore, Maryland, United States
Toledo, Ohio, United States
Long Beach, California, United States
Austin, Texas, United States
Fresno, California, United States
Albany, New York, United States
Walnut Creek, California, United States
Syracuse, New York, United States
Redondo Beach, California, United States
Tulsa, Oklahoma, United States
La Jolla, California, United States
Winston Salem, North Carolina, United States
Plano, Texas, United States
Jonesboro, Arkansas, United States
Bradenton, Florida, United States
Renton, Washington, United States
Tullahoma, Tennessee, United States
Tustin, California, United States
Greer, South Carolina, United States
Palm Beach Gardens, Florida, United States
Patients applied
Trial Officials
Johnson & Johnson Pharmaceutical Research and Development, L. L. C. Clinical Trial
Study Director
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials